Registered Attendees
Registered Attendees
Print This PageRegistered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
Close Window
Fairmont Chateau Whistler Floorplan
This meeting took place in 2013
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Meeting Details
Immunopathology of Type 1 Diabetes (Z1)
Organizer(s) Kevan C. Herold, Dario A.A. Vignali, Jeffrey A. Bluestone and Anne Cooke
April 4 - April 9, 2013
Fairmont Chateau Whistler • Whistler, British Columbia Canada
Abstract Deadline: December 4, 2012
Late Abstract Deadline: January 4, 2013
Scholarship Deadline: December 4, 2012
Early Registration Deadline: February 4, 2013
Supported by the Directors' Fund
CME Information
Joint Meeting:
Advances in the Knowledge and Treatment of Autoimmunity (Z2)
Summary of Meeting:
A great deal has been learned about the effectors and mechanisms of Type 1 diabetes from preclinical models and studies of samples from patients at risk and with the disease. However, despite this progress, translation of this understanding into new therapies that will have impact on patients has not been realized. The Keystone Symposia meeting on Immunopathology of Type 1 Diabetes will review our understanding of the mechanisms that are involved in the disease with consideration of the ways in which this understanding has resulted in clinical translation and how it has failed. Our goal is to integrate the most up to date understanding of mechanisms of autoimmune diabetes with studies in patients in order to identify ways in which developments in preclinical studies can provide insight into the past experiences in clinical studies and improve the design of future studies. The meeting will explore the following areas in detail: 1) What are the genetic determinants, immunopathology, and triggers of the disease? 2) What are the immune effectors that lead to beta cell destruction – how do they form and what are their functional characteristics? 3) How are immune effectors controlled in healthy individuals and how does this control fail in T1DM? 4) What has been the experience in restoring immune tolerance in humans – how can this be improved in the future? Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Advances in the Knowledge and Treatment of Autoimmunity, which will share a keynote address and two plenary sessions with this meeting.
CME Information
A great deal has been learned about the effectors and mechanisms of Type 1 diabetes from preclinical models and studies of samples from patients at risk and with the disease. However, despite this progress, translation of this understanding into new therapies that will have impact on patients has not been realized. The Keystone Symposia meeting on Immunopathology of Type 1 Diabetes will review our understanding of the mechanisms that are involved in the disease with consideration of the ways in which this understanding has resulted in clinical translation and how it has failed. Our goal is to integrate the most up to date understanding of mechanisms of autoimmune diabetes with studies in patients in order to identify ways in which developments in preclinical studies can provide insight into the past experiences in clinical studies and improve the design of future studies. The meeting will explore the following areas in detail: 1) What are the genetic determinants, immunopathology, and triggers of the disease? 2) What are the immune effectors that lead to beta cell destruction – how do they form and what are their functional characteristics? 3) How are immune effectors controlled in healthy individuals and how does this control fail in T1DM? 4) What has been the experience in restoring immune tolerance in humans – how can this be improved in the future? Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Advances in the Knowledge and Treatment of Autoimmunity, which will share a keynote address and two plenary sessions with this meeting.
Conference Program Print | View meeting in 12 hr (am/pm) time
THURSDAY, APRIL 4
19:15—21:30
Welcome and Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Kevan C. Herold,
Yale University, USA
Welcome Remarks
Welcome Remarks
*
Juan Rivera,
, USA
Luke A. J. O'Neill,
Trinity College Dublin, Ireland
Innate Immunity, Autoinflammation and Autoimmunity
Innate Immunity, Autoinflammation and Autoimmunity
*
Dario A. A. Vignali,
St. Jude Children's Research Hospital, USA
Diane J. Mathis,
Harvard Medical School, USA
Anti-Inflammatory Macrophages Regulate the Progression of T1D
Anti-Inflammatory Macrophages Regulate the Progression of T1D
08:00—11:30
Modulation of Immunity toward Autoimmune Therapy: From Mouse to Man (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
NOTE: The focus of this session is on the regulatory networks controlling immune response and the modulation of these processes towards amelioration of autoimmune disease.
*
Pere Santamaria,
University of Calgary, Canada
Dario A. A. Vignali,
St. Jude Children's Research Hospital, USA
Molecular Control of Treg Stability and Function
Molecular Control of Treg Stability and Function
Arlene H. Sharpe,
Harvard Medical School, USA
Control of Humoral Immunity by Lymph Node and Blood T Follicular Regulatory Cells
Control of Humoral Immunity by Lymph Node and Blood T Follicular Regulatory Cells
Alexander V. Chervonsky,
University of Chicago, USA
Microbial Influence on Type 1 Diabetes
Microbial Influence on Type 1 Diabetes
Jon D. Piganelli,
University of Pittsburgh, Children's Hospital, USA
Short Talk: Modulating the Bioenergetics of a Diabetogenic Immune Response
Short Talk: Modulating the Bioenergetics of a Diabetogenic Immune Response
Stephen D. Miller,
Northwestern University Medical School, USA
Induction of Immune Tolerance in the Treatment of Autoimmunity
Induction of Immune Tolerance in the Treatment of Autoimmunity
Maria Grazia Roncarolo,
San Raffaele Scientific Institute, Italy
Adaptive Immune Therapy with Regulatory T Cells for the Treatment of Autoimmunity
Adaptive Immune Therapy with Regulatory T Cells for the Treatment of Autoimmunity
17:00—19:00
Immune Effector/Autoantigens in T1DM
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Bart O. Roep,
Leiden University Medical Center, Netherlands
Emil R. Unanue,
Washington University School of Medicine, USA
Identifying Early Cellular and Genetic Events in NOD Diabetogenesis
Identifying Early Cellular and Genetic Events in NOD Diabetogenesis
Teresa P. DiLorenzo,
Albert Einstein College of Medicine, USA
Antigen-Specific T Cells in NOD Mouse Models of Diabetes
Antigen-Specific T Cells in NOD Mouse Models of Diabetes
Rachel S. Friedman,
National Jewish Health and University of Colorado, Denver, USA
Short Talk: T Cell Restimulation through Synaptic Contacts at the Autoimmune Disease Site Drives Effector Cytokine Production
Short Talk: T Cell Restimulation through Synaptic Contacts at the Autoimmune Disease Site Drives Effector Cytokine Production
17:00—19:00
Mechanisms of Peripheral and Central Tolerance
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
John W. Kappler,
HHMI/National Jewish Health, USA
Defining the Structural Nature of the Pathogenic CD4 T cell Ligands in NOD Type 1 Diabetes
Defining the Structural Nature of the Pathogenic CD4 T cell Ligands in NOD Type 1 Diabetes
*
Kristin V. Tarbell,
NIDDK, National Institutes of Health, USA
Diabetes, Dendritic Cells, and Induction of T Cell Tolerance
Diabetes, Dendritic Cells, and Induction of T Cell Tolerance
Shannon J. Turley,
Dana-Farber Cancer Institute, Harvard Medical School, USA
Interactions of DCs and T Cells with Lymphoid Stroma
Interactions of DCs and T Cells with Lymphoid Stroma
Brian D. Stadinski,
University of Massachusetts Medical School, USA
Short Talk: TCRalpha to TCRbeta Interactions Control Peptide Specificity and Self-Tolerance
Short Talk: TCRalpha to TCRbeta Interactions Control Peptide Specificity and Self-Tolerance
08:00—11:30
Regulatory and Developmental Control of T1DM
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Matthias G. von Herrath,
Novo Nordisk, USA
Mark S. Anderson,
University of California, San Francisco, USA
Immune Tolerance Mediated by Extrathymic Aire
Immune Tolerance Mediated by Extrathymic Aire
Stephan Kissler,
Joslin Diabetes Center, USA
Short Talk: The Type 1 Diabetes-Associated Gene CLEC16A Modulates Thymic Epithelial Cell Function and Impacts Central Tolerance
Short Talk: The Type 1 Diabetes-Associated Gene CLEC16A Modulates Thymic Epithelial Cell Function and Impacts Central Tolerance
Jeffrey A. Bluestone,
University of California, San Francisco, USA
Regulatory T Cells: Controlling Your (Immune) Temper
Regulatory T Cells: Controlling Your (Immune) Temper
Jane H. Buckner,
Benaroya Research Institute at Virginia Mason, USA
T Cell Deregulation in Human T1DM
T Cell Deregulation in Human T1DM
David A. Hafler,
Yale School of Medicine, USA
Common Non-Coding Variation at Enhancers Reveals Multi-lineage Contribution to Human Autoimmune Disease
Common Non-Coding Variation at Enhancers Reveals Multi-lineage Contribution to Human Autoimmune Disease
08:00—11:15
Innate Immunity and Autoimmune Disease
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
NOTE: Explores how innate immune cells play a role in the initiaition and progression of autoimmunity.
*
Silvia Bolland,
NIAID, National Institutes of Health, USA
TLR7-Induced NK Innate Lymphoid Cells
TLR7-Induced NK Innate Lymphoid Cells
Virginia Pascual,
Baylor Institute for Immunology Research, USA
Novel Myeloid Cell B Helper Pathways in SLE
Novel Myeloid Cell B Helper Pathways in SLE
Juan Rivera,
, USA
Auto-Reactive IgE and Basophils in the Amplification of SLE
Auto-Reactive IgE and Basophils in the Amplification of SLE
Melissa A. Brown,
Northwestern University, USA
Mast Cells in the Meninges: Orchestrators of Early Inflammation in CNS Disease
Mast Cells in the Meninges: Orchestrators of Early Inflammation in CNS Disease
Roland W. Kolbeck,
MedImmune, LLC, USA
Short Talk: LC3 Associated Phagocytosis Mediates IFNalpha Secretion in Response to DNA-Immune Complexes
Short Talk: LC3 Associated Phagocytosis Mediates IFNalpha Secretion in Response to DNA-Immune Complexes
Carla M. Cuda,
Northwestern University, USA
Short Talk: Caspase 8 Limits Dendritic Cell Activation
Short Talk: Caspase 8 Limits Dendritic Cell Activation
11:30—12:30
NIDDK Workshop: When is a Mechanism not a Mechanism? NIH Advice for Young Investigators
*
Lisa Spain,
NIDDK, National Institute of Health, USA
17:00—19:00
Workshop 1: Basic Research Advances
*
Anne Cooke,
University of Cambridge, UK
Imran S. Khan,
University of California, San Francisco, USA
MicroRNA Regulation of Thymic Epithelial Cell Biology and Central Tolerance
MicroRNA Regulation of Thymic Epithelial Cell Biology and Central Tolerance
Yong Fan,
University of Pittsburgh, USA
ID-TEC and ID-TEC-Rag Mice, Novel Animal Models for Studying Insulin Autoimmunity in Type 1 Diabetes
ID-TEC and ID-TEC-Rag Mice, Novel Animal Models for Studying Insulin Autoimmunity in Type 1 Diabetes
Maria Bettini,
St. Jude Children's Research Hospital, USA
TCR Affinity Shapes T Cell Pathogenicity and Susceptibility to Tolerance Mechanisms
TCR Affinity Shapes T Cell Pathogenicity and Susceptibility to Tolerance Mechanisms
Allyson M. Spence,
University of California, San Francisco, USA
Regulatory T Cell Commitment and Destabilization in the Inflamed Islets of NOD Mice
Regulatory T Cell Commitment and Destabilization in the Inflamed Islets of NOD Mice
Lindsey E. Padgett,
University of Alabama, Birmingham, USA
Reactive Oxygen Species Modulate CD4 T Cell Effector Responses in T1D
Reactive Oxygen Species Modulate CD4 T Cell Effector Responses in T1D
Karmel Allison,
University of California, San Diego, USA
Genome-Wide Sequencing of Nascent Transcripts in NOD Mouse Macrophages Reveals New Mechanisms of Innate Immune Disregulation in Type 1 Diabetes
Genome-Wide Sequencing of Nascent Transcripts in NOD Mouse Macrophages Reveals New Mechanisms of Innate Immune Disregulation in Type 1 Diabetes
Rochelle M. Hinman,
National Jewish Health, USA
Function and Fate of Insulin Reactive B Cells in Type 1 Diabetes
Function and Fate of Insulin Reactive B Cells in Type 1 Diabetes
Eliana Marino,
Monash University, Australia
A Strong Gut Feeling about the Cause of Type 1 Diabetes
A Strong Gut Feeling about the Cause of Type 1 Diabetes
17:00—19:00
Challenges and Lessons from Immunotherapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
NOTE: This session explores how identification of biomarkers and new treatments are advancing our knowledge of mechanisms and the pathophysiology underlying autoimmune disease and explores the challenges faced in the development and use of therapies in autoimmunity
*
Timothy W. Behrens,
Genentech, Inc., USA
Personalizing Medicine for Autoimmune and Inflammatory Diseases
Personalizing Medicine for Autoimmune and Inflammatory Diseases
Atul J. Butte,
Stanford University, USA
Transforming 300 Billion Points of Data into Diagnostics, Therapeutics, and New Insights into Immunological Disease
Transforming 300 Billion Points of Data into Diagnostics, Therapeutics, and New Insights into Immunological Disease
Robert P. Anderson,
ImmusanT, Inc., USA
Celiac Disease - Can We Transition from Peptides to Treatment?
Celiac Disease - Can We Transition from Peptides to Treatment?
Steven D. Levin,
Novo Nordisk, USA
Short Talk: IL21 Contributes to Human Autoimmune Disease through Multiple Mechanisms and IL21 Neutralization has Beneficial Effects in vitro
Short Talk: IL21 Contributes to Human Autoimmune Disease through Multiple Mechanisms and IL21 Neutralization has Beneficial Effects in vitro
17:00—19:00
Workshop 2: Translational/Clinical Research Advances
*
Kevan C. Herold,
Yale University, USA
Matthew M. Rankin,
Children's Hospital of Philadelphia, USA
Increased Islet Replication and Persistent Insulitis in Pancreata from Adolescent T1D Patients
Increased Islet Replication and Persistent Insulitis in Pancreata from Adolescent T1D Patients
Gaetano Faleo,
University of California, San Francisco, USA
Protection of Allogeneic Cells from Alloimmune-Mediated Rejection Using Macroencapsulation
Protection of Allogeneic Cells from Alloimmune-Mediated Rejection Using Macroencapsulation
Melanie Stumpf,
University of Colorado Denver, USA
Identification of Disease-Associated TCR alpha and beta Chains Directly from Pancreas Tissue of T1D Patients
Identification of Disease-Associated TCR alpha and beta Chains Directly from Pancreas Tissue of T1D Patients
Nalini K. Vudattu,
Yale University, USA
The Study of Autoimmune Disease in Humanized Mice
The Study of Autoimmune Disease in Humanized Mice
Rachel A. Henry-Bonami,
Vanderbilt University, USA
Autoantigen-Targeted Therapy: Stopping Anti-Insulin B Cells from Giving T Cells Bad Advice
Autoantigen-Targeted Therapy: Stopping Anti-Insulin B Cells from Giving T Cells Bad Advice
Brian T. Fife,
University of Minnesota, USA
Indirect Presentation of Antigen-Coupled Cells Mediates Specific CD4+ T Cell Tolerance for the Prevention of T1D
Indirect Presentation of Antigen-Coupled Cells Mediates Specific CD4+ T Cell Tolerance for the Prevention of T1D
Sofie Robert,
KU Leuven, Belgium
Islet Autoantigens Delivered by L. lactis in the Gut Together with hIL-10 Revert Diabetes in Recent-Onset NOD Mice when Combined with Low-Dose Anti-CD3
Islet Autoantigens Delivered by L. lactis in the Gut Together with hIL-10 Revert Diabetes in Recent-Onset NOD Mice when Combined with Low-Dose Anti-CD3
Michael D. McHugh,
Yale University, USA
Induction of Tolerance in Type 1 Diabetes Using Biodegradable Nanoparticles
Induction of Tolerance in Type 1 Diabetes Using Biodegradable Nanoparticles
08:00—11:30
The Microflora in the Regulation of Immunity and Autoimmunity (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
NOTE: Reviews recent advance on the microbiomes influence in initiation, progression, and regulation of immune responses and autoimmune disease.
George M. Weinstock,
Washington University School of Medicine, USA
Overview of the Human Microbiome: A New Frontier that just Might Affect Everything
Overview of the Human Microbiome: A New Frontier that just Might Affect Everything
*
Jayne S. Danska,
Hospital for Sick Children Research Institute, Canada
The Gut Microbiome Drives Hormone-Dependent Regulation of Type 1 Diabetes
The Gut Microbiome Drives Hormone-Dependent Regulation of Type 1 Diabetes
Fiona M. Powrie,
University of Oxford, UK
Microbiome-Induced IL-23 Promotes Intestinal Inflammation and Colon Cancer
Microbiome-Induced IL-23 Promotes Intestinal Inflammation and Colon Cancer
Mark A. Atkinson,
University of Florida, USA
The Role for the Gut Microbiome in Type 1 Diabetes – Early Lessons from Humans and NOD Mice
The Role for the Gut Microbiome in Type 1 Diabetes – Early Lessons from Humans and NOD Mice
Joseph Larkin III,
University of Florida, USA
Short Talk: Antigen Presenting Cell Interactions with Gut Flora Modulate Diabetogenic T Lymphocyte Effector Functions
Short Talk: Antigen Presenting Cell Interactions with Gut Flora Modulate Diabetogenic T Lymphocyte Effector Functions
Lloyd H. Kasper,
Geisel School of Medicine at Dartmouth, USA
Role of Commensal Bacteria in the Regulation of Central Nervous System Disease Demyelination
Role of Commensal Bacteria in the Regulation of Central Nervous System Disease Demyelination
14:30—16:30
Workshop 1: Basic Mechanisms in Autoimmunity
*
Shannon J. Turley,
Dana-Farber Cancer Institute, Harvard Medical School, USA
Rachel R. Caspi,
NEI, National Institutes of Health, USA
IL-27p28 Inhibits CNS Autoimmunity by Concurrently Antagonizing Th1 and Th17 Responses
IL-27p28 Inhibits CNS Autoimmunity by Concurrently Antagonizing Th1 and Th17 Responses
Tian Chi,
Yale University, USA
BRG1-Mediated Immune Tolerance: Facilitation of Treg Activation and Partial Independence of Chromatin Remodeling
BRG1-Mediated Immune Tolerance: Facilitation of Treg Activation and Partial Independence of Chromatin Remodeling
Benoit L. Salomon,
University Pierre et Marie Curie, France
TNFalpha /TNFR2 Pathway Is Critical for EAE Remission and Treg Expansion in the Central Nervous System
TNFalpha /TNFR2 Pathway Is Critical for EAE Remission and Treg Expansion in the Central Nervous System
Jianmei W. Leavenworth,
Dana-Farber Cancer Institute, USA
Amelioration of Arthritis through Mobilization of Peptide-Specific CD8+ Regulatory T-Cells
Amelioration of Arthritis through Mobilization of Peptide-Specific CD8+ Regulatory T-Cells
Natalia V. Giltiay,
Washington University, USA
Antigen Delivery to pDCs through hBDCA2 Leads to Reduction of Effector T-Cell Activation and Ag-Specific Ab Responses
Antigen Delivery to pDCs through hBDCA2 Leads to Reduction of Effector T-Cell Activation and Ag-Specific Ab Responses
Rajat Varma,
LSB, NIAID, National Institutes of Health, USA
T Cell Receptor Microclusters are Platforms for Ligand Discrimination
T Cell Receptor Microclusters are Platforms for Ligand Discrimination
14:30—16:30
Workshop 2: Clinical and Translational Aspects of Autoimmunity
*
Jane H. Buckner,
Benaroya Research Institute at Virginia Mason, USA
Simone Caielli,
Baylor Institute Immunology Research, USA
SLE Neutrophil-Derived DAMPs Activate pDCs to Induce a Lupus-Specific CD4 T Cell Phenotype
SLE Neutrophil-Derived DAMPs Activate pDCs to Induce a Lupus-Specific CD4 T Cell Phenotype
Barbara Dema,
NIAMS, National Institutes of Health, USA
Prevalence of Auto-Reactive IgE and Activated Basophils in Systemic Lupus Erythematosus
Prevalence of Auto-Reactive IgE and Activated Basophils in Systemic Lupus Erythematosus
Gabriela Hernandez-Hoyos,
Emergent BioSolutions (EBSI), USA
A Bi-Specific ADAPTIR Molecule that Targets CD86 and Delivers IL-10 Inhibits Antigen Presenting Cells and Has Potential as a Therapeutic Treatment of Autoimmune Disease
A Bi-Specific ADAPTIR Molecule that Targets CD86 and Delivers IL-10 Inhibits Antigen Presenting Cells and Has Potential as a Therapeutic Treatment of Autoimmune Disease
Silvia Preite,
Institute for Research in Biomedicine, Switzerland
Regulation of T Helper Cell-Dependent Antibody Response in Lymphopenic Hosts
Regulation of T Helper Cell-Dependent Antibody Response in Lymphopenic Hosts
Yasuko Furumoto,
NIAMS, National Institutes of Health, USA
Tofacitinib Inhibits Cell Metabolism in Activated T Cells
Tofacitinib Inhibits Cell Metabolism in Activated T Cells
Catia Verbeke,
Harvard University, USA
Antigen-Specific Immune Modulation Using an Injectable Biomaterial
Antigen-Specific Immune Modulation Using an Injectable Biomaterial
17:00—19:00
Immune Modulation and Effects of Immune Modulators on T1DM
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Fiona M. Powrie,
University of Oxford, UK
Matthias G. von Herrath,
Novo Nordisk, USA
Learning from Human Immunopathology to Develop Rational Treatments for Type 1 Diabetes
Learning from Human Immunopathology to Develop Rational Treatments for Type 1 Diabetes
Lucienne Chatenoud,
INSERM U1013, Hôpital Necker-Enfants Malades, France
CD3 Antibodies in Established Autoimmunity: A Glass Half Empty or Half Full?
CD3 Antibodies in Established Autoimmunity: A Glass Half Empty or Half Full?
Thomas R. Malek,
University of Miami School of Medicine, USA
Short Talk: Human T Regulatory Cells Are Intrinsically More Sensitive to IL-2-Induced Signal Transduction Than T Effector and T Memory Cells
Short Talk: Human T Regulatory Cells Are Intrinsically More Sensitive to IL-2-Induced Signal Transduction Than T Effector and T Memory Cells
Bart O. Roep,
Leiden University Medical Center, Netherlands
Methods and Mechanisms of Immune Modulation in Humans
Methods and Mechanisms of Immune Modulation in Humans
17:00—19:00
Lymphocytes in Autoimmunity I - B Cells
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
NOTE: Covers recent advances on B cells as promoters and regulators of immune responses and autoimmunity.
*
David M. Lee,
Novartis Institutes for Biomedical Research, Switzerland
Eric Meffre,
Yale University School of Medicine, USA
Impact of Gene Mutations and Polymorphisms on Human B-Cell Tolerance
Impact of Gene Mutations and Polymorphisms on Human B-Cell Tolerance
Andreas Radbruch,
Deutsches Rheuma-Forschungszentrum, Berlin, Germany
Plasmablasts vs. Plasma Cells - Roles in Autoantibody Production
Plasmablasts vs. Plasma Cells - Roles in Autoantibody Production
Thomas F. Tedder,
Duke University Medical Center, USA
Regulatory B Cells in Health and Disease: B10 Cells Negatively Regulate Autoimmunity
Regulatory B Cells in Health and Disease: B10 Cells Negatively Regulate Autoimmunity
Mohini K. Gray,
MRC Centre for Inflammation Research, Scotland
Short Talk: A Tolerogenic Role for Toll-Like Receptor 9 Is Revealed by Regulatory B-Cell Interaction with Apoptotic Cells
Short Talk: A Tolerogenic Role for Toll-Like Receptor 9 Is Revealed by Regulatory B-Cell Interaction with Apoptotic Cells
08:00—11:30
Cellular and Environmental Networks in T1DM
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Dario A. A. Vignali,
St. Jude Children's Research Hospital, USA
Li Wen,
Yale University, USA
Role of TLRs in Regulation of Autoimmunity and Beta Cells in Type 1 Diabetes
Role of TLRs in Regulation of Autoimmunity and Beta Cells in Type 1 Diabetes
Anne Cooke,
University of Cambridge, UK
Epigenetic Modification of Induced Treg Cells: Implications for Therapy
Epigenetic Modification of Induced Treg Cells: Implications for Therapy
Agnès C. Lehuen,
, France
NKT Cells and Plasmacytoid DC in Type 1 Diabetes in Infectious and Non-Infectious Context
NKT Cells and Plasmacytoid DC in Type 1 Diabetes in Infectious and Non-Infectious Context
David V. Serreze,
The Jackson Laboratory, USA
To Be or Not To Be: Challenges in B-Lymphocyte Directed Interventions for Autoimmune Diabetes
To Be or Not To Be: Challenges in B-Lymphocyte Directed Interventions for Autoimmune Diabetes
Lucy S. K. Walker,
University College London, UK
Short Talk: Roles for IL-21 in Modulating T and B Cell Immunity in Autoimmune Diabetes
Short Talk: Roles for IL-21 in Modulating T and B Cell Immunity in Autoimmune Diabetes
Megan K. Levings,
University of British Columbia, Canada
Molecular and Functional Properties of Regulatory T Cells
Molecular and Functional Properties of Regulatory T Cells
08:00—11:15
Lymphocytes in Autoimmunity II - T Cells
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
NOTE: Discussion of T cell function in immunity and autoimmunity with emphasis on human immunology.
Federica Sallusto,
Institute for Research in Biomedicine, Switzerland
T Cell Subsets in Human Disease
T Cell Subsets in Human Disease
Shigeo Koyasu,
Keio University School of Medicine, Japan
Role of Natural Helper Cell, a Member of the ILC (ILC2) in Steroid Resistance of Allergic Inflammation
Role of Natural Helper Cell, a Member of the ILC (ILC2) in Steroid Resistance of Allergic Inflammation
*
Carola G. Vinuesa,
Australian National University, Australia
Control of Tfh Cells
Control of Tfh Cells
Vijay K. Kuchroo,
Brigham and Women's Hospital, Harvard Medical School, USA
Unexpected Targets and Triggers of Autoimmunity
Unexpected Targets and Triggers of Autoimmunity
Xuezhi Dai,
Seattle Childrens' Research Institute, USA
Short Talk: The PTPN22 Risk Variant Promotes Systemic Autoimmunity in Murine Models
Short Talk: The PTPN22 Risk Variant Promotes Systemic Autoimmunity in Murine Models
Anne R. Gocke,
Johns Hopkins University, USA
Short Talk: Kv1.3 Deletion Induces Foxo1 Expression and Biases TH Cells Toward an Immunoregulatory Phenotype Independently of Foxp3
Short Talk: Kv1.3 Deletion Induces Foxo1 Expression and Biases TH Cells Toward an Immunoregulatory Phenotype Independently of Foxp3
11:30—12:30
NIDDK Planning Meeting: Future Needs and Priorities for Type 1 Diabetes Research
*
Beena Akolkar,
NIDDK, National Institutes of Health, USA
17:00—19:00
The Future of T1DM Research and Clinical Translation
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Jeffrey A. Bluestone,
University of California, San Francisco, USA
Linda S. Wicker,
University of Cambridge, UK
IL-2 Therapy for Type 1 Diabetes
IL-2 Therapy for Type 1 Diabetes
Paul L. Bollyky,
Stanford University, USA
Short Talk: Hyaluronan Promotes Tonic STAT5 Signaling in Human Treg But this Effect Is Impaired in Type 1 Diabetes
Short Talk: Hyaluronan Promotes Tonic STAT5 Signaling in Human Treg But this Effect Is Impaired in Type 1 Diabetes
Kevan C. Herold,
Yale University, USA
Combination Therapies for Type 1 Diabetes
Combination Therapies for Type 1 Diabetes
Gerald T. Nepom,
Benaroya Research Institute, USA
Next-Generation Therapeutic Opportunities and Challenges in T1D
Next-Generation Therapeutic Opportunities and Challenges in T1D
17:00—19:00
Systems Approaches to Autoimmunity
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
NOTE: What information is being gained by a systems approach toward the study of autoimmunity and how can we best utilize these vast data sets?
*
Virginia Pascual,
Baylor Institute for Immunology Research, USA
Edward K. Wakeland,
University of Texas Southwestern Medical Center, USA
Genomic Analysis of Susceptibility to Autoimmunity
Genomic Analysis of Susceptibility to Autoimmunity
Soumya Raychaudhuri,
Brigham and Women's Hospital, Harvard Medical School, USA
Genetics, Epigenetics, and Functional Genomics to Identify Critical Host Cell-Types in Autoimmunity
Genetics, Epigenetics, and Functional Genomics to Identify Critical Host Cell-Types in Autoimmunity
Bernd Wollscheid,
ETH Zurich, Switzerland
Short Talk: Caught in the Act: LCR Technique for the Direct Identification of Endogenous Ligand-Receptor Interaction on Cells and Tissue
Short Talk: Caught in the Act: LCR Technique for the Direct Identification of Endogenous Ligand-Receptor Interaction on Cells and Tissue
*Session Chair †Speaker invited, not yet responded.
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Amanda Deem, Assistant
Director of Development, Email: AmandaD@keystonesymposia.org, Phone:+1 970-262-2668 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
